PB1885: PHASE 1 STUDY OF ZIFTOMENIB IN COMBINATION WITH VENETOCLAX, VENETOCLAX/AZACITIDINE, OR STANDARD INDUCTION (7 + 3) CHEMOTHERAPY IN PATIENTS WITH ACUTE MYELOID LEUKEMIA

Liknande verk

• Pharmacokinetics and ADME Characterization After Oral and Intravenous Administration of [14C]‐Ziftomenib in Healthy Male Participants
  av: Amitava Mitra, et al.
  Utgiven: (2025-02-01)
• PB1885: PHASE 1 STUDY OF ZIFTOMENIB IN COMBINATION WITH VENETOCLAX, VENETOCLAX/AZACITIDINE, OR STANDARD INDUCTION (7 + 3) CHEMOTHERAPY IN PATIENTS WITH ACUTE MYELOID LEUKEMIA
  av: Amer M Zeidan, et al.
  Utgiven: (2023-08-01)
• Population Pharmacokinetics and Exposure‐Response Analysis of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia Patients With NPM1 Mutation
  av: Amitava Mitra, et al.
  Utgiven: (2026-05-01)
• Menin inhibitor ziftomenib (KO-539) synergizes with drugs targeting chromatin regulation or apoptosis and sensitizes acute myeloid leukemia with <i>MLL</i> rearrangement or <i>NPM1</i> mutation to venetoclax
  av: Johanna Rausch, et al.
  Utgiven: (2023-04-01)
• PB1761: PRECLINICAL EVALUATION OF THE MENIN INHIBITOR ZIFTOMENIB IN PRIMARY AML SPECIMENS
  av: Brett Stevens, et al.
  Utgiven: (2023-08-01)